Mérieux, a world leader in the field of in vitro diagnostics, announces the launch of BIOFIRE® SPOTFIRE® for pharmaceutical industries, where this innovative molecular testing system is designed to ...
BioFire Diagnostics Inc. has raised $25 million in new funding from New York-based Athyrium Opportunities Fund. The money will be used to help commercialize the company’s “FilmArray” diagnostic ...
In a landmark step toward advancing infectious disease diagnostics, Asiri Laboratories has introduced the BioFire FilmArray ...
MARCY L’ETOILE, France--(BUSINESS WIRE)--Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, LLC, its molecular ...
SALT LAKE CITY--(BUSINESS WIRE)--BioFire Diagnostics, Inc., today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8,394,608 covering the company’s FilmArray ...
BioFire Diagnostics won 510(k) clearance for its gastrointestinal panel for infectious diarrhea, following in the footsteps of the company's acquisition by French diagnostic giant bioMérieux.
SALT LAKE CITY, Utah (March 26, 2013) — BioFire Diagnostics, Inc. today announced that it has signed a competitive prototyping contract with the Department of the Army for Increment 1 of the Next ...
BioFire Diagnostics may have agreed to sell itself to French diagnostics giant bioMérieux for $450 million, but the company plans to keep its name and senior management and continue growing at its ...
US FDA grants BioFire Diagnostics to market CSF nucleic acid-based test to detect multiple pathogens
The US Food and Drug Administration (FDA) allowed Salt Lake City, Utah-based BioFire Diagnostics to market the first cerebrospinal fluid (CSF) nucleic acid-based test for simultaneous detection of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results